Here are the 10-Q quarterly reports from STERIS plc (STE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow STE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STE filings page.
STERIS plc (STE) reported second-quarter fiscal 2027 revenue of $1,588.6 million, up 8.8% from $1,460.3 million a year earlier. Net income attributable to shareholders was $213.7 million versus $191.9 million, while income from operations was $294.3 million versus $265.8 million. Gross profit percentage was 44.7%, compared with 44.2%.
For the first six months of fiscal 2027, operating cash flow was $656.1 million and free cash flow was $492.5 million, down from $707.8 million and $527.7 million, respectively. STERIS attributed the decreases to a lower working-capital contribution as cash was used to build inventory, partly offset by higher net income.
Two fiscal 2027 restructuring plans carry separate projected charges: approximately $55 million to $70 million in pre-tax charges for a manufacturing and distribution consolidation, with completion anticipated during fiscal 2030, and approximately $45 million for portfolio and organizational changes, anticipated to be substantially complete by the end of fiscal 2028. STERIS also entered into an agreement to acquire Xodus Medical for approximately $2.1 billion in cash at closing, plus potential earnout consideration of up to $150 million; closing is anticipated by December 31, 2026, subject to customary closing conditions and regulatory approvals.
STERIS plc reported stronger fiscal 2027 first‑quarter results, with revenue up 7.3% to $1,492.7 million, driven by higher volume in Healthcare and Life Sciences and pricing across all segments. Product revenue was $737.2 million and service revenue $755.5 million.
Gross margin improved to 45.8% from 45.1% as pricing, productivity and mix more than offset inflation. Income from operations rose to $285.8 million from $246.0 million, while net income attributable to shareholders increased to $200.1 million, or $2.04 diluted EPS, from $177.4 million, or $1.79.
Operating cash flow was $367.1 million and free cash flow $279.6 million after $87.5 million of capital spending. Total debt was $1,893.7 million, giving a debt‑to‑total capital ratio of 20.9%. The company repurchased 0.5 million shares for $100.0 million and began a new $1,000.0 million buyback program with $900.0 million remaining.
Remaining performance obligations were $1,541.4 million, with most expected to convert to revenue within a year. After largely completing a prior European restructuring, STERIS announced a new North Carolina chemistries consolidation, expecting $55–$70 million of pre‑tax restructuring charges through fiscal 2030.
STERIS plc reported solid growth for the nine months ended December 31, 2025. Total revenues rose to $4,347.5 million from $3,979.0 million, with balanced increases in Healthcare, AST, and Life Sciences. Net income attributable to shareholders grew to $562.1 million, and diluted EPS from continuing operations increased to $5.69 from $4.68.
Gross profit reached $1,929.4 million, while operating income from continuing operations improved to $785.0 million, despite $5.1 million of acquisition and integration expenses and $3.0 million of restructuring costs. Cash flow from operating activities was strong at $1,006.0 million, supporting capital expenditures of $278.8 million and share repurchases of $161.2 million plus $180.0 million in dividends.
The balance sheet showed cash and cash equivalents of $423.7 million and total debt of $1,898.4 million, with shareholders’ equity rising to $7,154.5 million. The company completed the Dental segment sale (reported as discontinued operations) and continues to manage restructuring in its Healthcare surgical business in Europe and an ethylene oxide litigation settlement framework in Illinois, as well as ongoing IRS tax matters.
STERIS plc reported stronger quarterly results for the three months ended September 30, 2025. Revenue rose to $1,460.3 million from $1,328.9 million as Healthcare delivered $1,033.8 million, Applied Sterilization Technologies $281.5 million, and Life Sciences $145.0 million. Operating income increased to $265.8 million from $219.7 million, with net income attributable to shareholders of $191.9 million (diluted EPS $1.94) versus $150.0 million ($1.51) a year ago. The effective tax rate was 23.9%.
Through six months, operating cash flow was $707.8 million, funding capital spending of $180.1 million and supporting cash balances of $319.2 million. Total debt declined to $1,897.3 million from $2,043.7 million. The company repurchased 0.4 million shares for $100.0 million and paid dividends of $1.20 per share year-to-date. Remaining performance obligations were $1,926.4 million, with approximately 53% expected to be recognized within one year.